Regeneron Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	14,920	14,343	14,202	13,117	12,173	16,072
Revenue Growth (YoY)	5.92%	0.99%	8.27%	7.76%	-24.26%	89.14%
Cost of Revenue	2,306	2,101	1,971	1,816	1,560	2,438
Gross Profit	12,614	12,242	12,232	11,301	10,613	13,634
Selling, General & Admin	2,715	2,700	2,954	2,631	2,116	1,825
Research & Development	6,280	5,974	5,233	4,625	3,848	2,908
Other Operating Expenses	-10	-10	53.4	-2.1	-89.9	-45.6
Total Operating Expenses	8,985	8,664	8,241	7,254	5,874	4,687
Operating Income	3,629	3,578	3,991	4,047	4,739	8,947
Interest Expense	-48	-43.8	-55.2	-73	-59.4	-57.3
Other Non-Operating Income (Expense)	1,576	1,697	844.4	225.2	179.3	436.3
Total Non-Operating Income (Expense)	1,528	1,653	789.2	152.2	119.9	379
Pretax Income	5,157	5,231	4,780	4,199	4,859	9,326
Provision for Income Taxes	733.5	725.8	367.3	245.7	520.4	1,251
Net Income	4,423	4,505	4,413	3,954	4,338	8,075
Net Income to Common	4,423	4,505	4,413	3,954	4,338	8,075
Net Income Growth	-1.69%	2.09%	11.61%	-8.87%	-46.28%	129.86%
Shares Outstanding (Basic)	104	105	108	107	107	106
Shares Outstanding (Diluted)	108	109	115	114	114	112
Shares Change (YoY)	-5.61%	-5.65%	1.23%	0.18%	1.16%	-2.52%
EPS (Basic)	42.53	43.07	40.90	37.05	40.51	76.40
EPS (Diluted)	41.04	41.48	38.34	34.77	38.22	71.97
EPS Growth	4.48%	8.19%	10.27%	-9.03%	-46.89%	135.81%
Shares Outstanding	105	105.7	109.6	109.4	109.6	108.68
Free Cash Flow	4,113	4,081	3,665	3,875	4,425	6,529
Free Cash Flow Growth	0.80%	11.35%	-5.44%	-12.42%	-32.23%	225.90%
Free Cash Flow Per Share	38.17	37.57	31.84	34.08	38.98	58.19
Dividends Per Share	3.580	3.520	-	-	-	-
Dividend Growth	1.70%	-	-	-	-	-
Gross Margin	84.55%	85.35%	86.13%	86.16%	87.18%	84.83%
Operating Margin	24.32%	24.95%	28.10%	30.85%	38.93%	55.67%
Profit Margin	29.65%	31.41%	31.07%	30.14%	35.64%	50.25%
FCF Margin	27.57%	28.45%	25.80%	29.54%	36.35%	40.63%
EBITDA	4,169	4,122	4,474	4,468	5,080	9,233
EBITDA Margin	27.94%	28.74%	31.50%	34.06%	41.73%	57.45%
EBIT	3,629	3,578	3,991	4,047	4,739	8,947
EBIT Margin	24.32%	24.95%	28.10%	30.85%	38.93%	55.67%
Effective Tax Rate	14.22%	13.88%	7.68%	5.85%	10.71%	13.41%

Updated Apr 29, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q